ubiquitin conjugating enzyme E2 C pseudogene 3Genealiases: []
Q-omics provides the consensus-scored UBE2CP3 profile across patient tissues and cancer cell-line models. UBE2CP3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, UBE2CP3 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, UBE2CP3 RNA expression shows 20,019 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KICH, and GBM as cancer lineages where UBE2CP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2CP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2CP3 survival associations across molecular data types. UBE2CP3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2CP3 RNA expression–survival associations across cancer types. High UBE2CP3 expression shows unfavorable associations in UVM, TGCT, ACC, UCS and THYM, but favorable associations in LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for UBE2CP3 RNA expression.
This table summarizes UBE2CP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2CP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2CP3 shows lower tumor expression in KICH, KIRC and KIRP and higher tumor expression in COAD and HNSC. The KICH box plot shows higher UBE2CP3 RNA expression in normal versus tumor tissue (log2 FC = −0.560, t-test p < 0.001).
This table shows molecular features associated with UBE2CP3 in patient tissues and cancer cell lines. In patient samples, UBE2CP3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
